Our Pipeline
Entwicklungsprogramme
Abivax is in the process of transforming into a commercial-stage company through opportunities to potentially harness the novel mechanism of action of microRNA-124, with our lead product candidate, obefazimod, and beyond.
Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases, starting with ulcerative colitis. We expect top-line induction results from the Phase 3 ABTECT program in Q1 2025 and top-line maintenance results in Q1 2026.
Our proprietary chemical library represents further untapped possibilities. We have launched a research effort, based on the mechanistic concept of obefazimod, to discover new potential follow-on drug candidates.
Active Abivax Pipeline
Obefazimod follow-on candidate selection is expected in Q3 2024.